New drug cocktail aims to stop kidney rejection in transplant patients

This study tested whether a drug called bortezomib, given with steroids, plasma exchange, and immunoglobulins, can treat chronic antibody-mediated rejection in kidney transplant recipients. The trial included 60 adults who had a kidney transplant and developed donor-specific antibodies. The goal was to see if this combination could reduce signs of rejection in kidney tissue and lower harmful antibody levels.